Agenda
| Opening Remarks Dr. Lawrence A. Leiter |
| Improving quality of life in heart failure with SGLT2 inhibitors: Results from an EMPEROR Reduced Sub-Analysis Dr. Shelley Zieroth |
| VASCEPA-COVID-19: First randomized trial of Icosapent Ethyl in ambulatory Canadian patients with COVID-19 Dr. Subodh Verma |
| Clinical Implications of VASCEPA COVID-19 Dr. Lawrence A. Leiter |
| Q & A Panel Discussion |
| Keynote presentation:The STRENGTH of REDUCE-IT Dr. Deepak L. Bhatt |
| Closing Remarks Dr. Lawrence A. Leiter |
Faculty
Lawrence A. Leiter
MD, FRCPC, FACP, FACE, FAHA, FACC
CHAIR
Endocrinologist, St. Michael’s Hospital;
Professor of Medicine and Nutritional
Sciences, University of Toronto,
Toronto, ON, Canada
Deepak L. Bhatt
MD, MPH, FACC, FAHA, FSCAI, FESC
KEYNOTE SPEAKER
Cardiologist, Executive Director of
Interventional Cardiovascular Programs,
Brigham and Women’s Hospital
Heart & Vascular Center;
Professor of Medicine,
Harvard Medical School,
Boston, MA, USA
Subodh Verma
MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St. Michael’s Hospital;
Professor of Surgery and Pharmacology &
Toxicology, University of Toronto; Canada
Research Chair in Cardiovascular Surgery,
Toronto, ON, Canada
Shelley Zieroth
MD, FRCPC, FCCS, FHFSA, FESC, FACC
Cardiologist and Director, St. Boniface
Hospital Heart Failure and Transplant
Clinics; Head, Medical Heart Failure
Program, WRHA Cardiac Sciences
Program; Associate Professor of Medicine,
University of Manitoba; Immediate Past-
President Canadian Heart Failure Society;
Winnipeg, MB, Canada
Video Information
- Credit:No Credit Available
- Post Date:December 30, 2020
- Expiry Date:N/A
